Top

Published in:

01-03-2009

Treatment of depression in patients with congestive heart failure

Author: Peter A. Shapiro

Published in: Heart Failure Reviews | Issue 1/2009

Abstract

Heart failure is common, and depression is common in heart failure patients, adding substantially to the burden of the disease. There is some evidence for the safe and at least modestly effective use of psychotherapy and antidepressants to treat depression in heart failure patients. Cognitive behavioral psychotherapy and selective serotonin reuptake inhibitors are first line treatments. The efficacy of depression treatment in altering cardiac outcomes in heart failure patients has yet to be established.

Rosamond W, Flegal K, Friday G et al (2007) Heart disease and stroke statistics–2007 update: a report from the American heart association statistics committee and stroke statistics subcommittee. Circulation 115, e69–171PubMedCrossRef

Koenig HG (1998) Depression in hospitalized older patients with congestive heart failure. Gen Hosp Psychiatry 20:29–43PubMedCrossRef

Jiang W, Alexander J, Christopher E et al (2001) Relationship of depression to increased risk of mortality and rehospitalization in patients with congestive heart failure. Arch Intern Med 161:1849–1856PubMedCrossRef

Rumsfeld JS, Havranek E, Masoudi FA et al (2003) Depressive symptoms are the strongest predictors of short-term declines in health status in patients with heart failure. J Am Coll Cardiol 42:1811–1817PubMedCrossRef

Ruo B, Rumsfeld JS, Hlatky MA, Liu H, Browner WS, Whooley MA (2003) Depressive symptoms and health-related quality of life: the heart and soul study. JAMA 290(2):215–221

Faris R, Purcell H, Henein MY, Coats AJS (2002) Clinical depression is common and significantly associated with reduced survival in patients with non-ischaemic heart failure. Eur J Heart Fail 4(4):541–551

Freedland KE, Carney RM, Davila-Roman VG, Rich MW, Skala JA, Jaffe AS. (1998) Major depression and survival in congestive heart failure. Psychosom Med 60:118

Roose SP, Glassman AH (1989) Cardiovascular effects of tricyclic antidepressants in depressed patients with and without heart disease. J Clin Psychiatry 50:S1–18

Roose SP, Glassman AH, Dalack GW (1989) Depression, heart disease, and tricyclic antidepressants. J Clin Psychiatry 50:12–16PubMed

10.

Roose SP, Glassman AH, Giardina EGV et al (1986) Nortriptyline in depressed patients with left ventricular impairment. JAMA 256:3253–3257PubMedCrossRef

11.

CAST Investigators (1989) Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 321:406–412CrossRef

12.

Echt DS, Liebson PR, Mitchelle LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide or placebo. N Engl J Med 324:781–788PubMedCrossRef

13.

CAST II Investigators (1992) Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 327:227–233

14.

Morganroth J, Goin JE (1991) Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias. Circulation 84:1977–1983PubMed

15.

Glassman AH, Roose SP, Bigger JT Jr (1993) The safety of tricyclic antidepressants in cardiac patients. Risk-benefit reconsidered. JAMA 269:2673–2675PubMedCrossRef

16.

Sheline YI, Freedland KE, Carney RM (1997) How safe are serotonin reuptake inhibitors for depression in patients with coronary heart disease? Am J Med 102(1):54–59PubMedCrossRef

17.

Shapiro PA (2004) Heart disease. In: Levenson JL (ed) APPI textbook of psychosomatic medicine. APPI, Washington, D.C., pp 423–444

18.

Roose SP, Glassman AH, Attia E, Woodring S (1994) Comparative efficacy of selective serotonin reuptake inhibitors and tricyclics in the treatment of melancholia. Am J Psychiatry 151:1735–1739PubMed

19.

Roose SP, Glassman AH, Attia E, Woodring S, Giardina EGV, Bigger JT (1998) Cardiovascular effects of fluoxetine in depressed patients with heart disease. Am J Psychiatry 155:660–665PubMed

20.

Roose SP, Laghrissi-Thode F, Kennedy JS et al (1998) Comparison of paroxetine and nortriptyline in depressed patients with ischemic heart disease. JAMA 279:287–291PubMedCrossRef

21.

Strik JJMH, Honig A, Lousberg R et al (2000) Efficacy and safety of fluoxetine in the treatment of patients with major depression after first myocardial infarction: findings from a double-blind, placebo-controlled trial. Psychosom Med 62(6):783–789

22.

Glassman AH, O’Connor CM, Califf RM et al (2002) Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 288:701–709PubMedCrossRef

23.

Glassman AH, Bigger JT, Gaffney M, Shapiro PA, Swenson JR. (2006) Onset of major depression associated with acute coronary syndromes. Relationship of onset, major depressive disorder history, and episode severity to sertraline benefit. Arch Gen Psychiatry 63:283–288PubMedCrossRef

24.

Lesperance F, Frasure-Smith N, Koszycki D et al (2007) Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian cardiac randomized evaluation of antidepressant and psychotherapy efficacy (CREATE) trial. JAMA 297(4):367–379

25.

Musselman DL, Tomer A, Manatunga AK et al (1996) Exaggerated platelet reactivity in major depression. Am J Psychiatry 153:1313–1317PubMed

26.

Laghrissi-Thode F, Wagner WR, Pollack BG, Johnson PC, Finkel MS. (1997) Elevated platelet factor 4 and beta-thromboglogulin plasma levels in depressed patients with ischemic heart disease. Biol Psychiatry 42:290–295PubMedCrossRef

27.

Pollock BG, Laghrissi-Thode F, Wagner WR (2000) Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 20(2):137–140PubMedCrossRef

28.

Serebruany VL, Glassman AH, Malinin AI et al (2003) Selective serotonin reuptake inhibitors yield additional antiplatelet protection in patients with congestive heart failure treated with antecedent aspirin. Eur J Heart Fail 5:517–521PubMedCrossRef

29.

Serebruany VL, Glassman AH, Malinin AI et al (2003) Platelet/endothelial biomarkers in depressed patients treated with the selective serotonin reuptake inhibitor sertraline after acute coronary events: the sertraline antidepressant heart attack randomized trial (SADHART) platelet substudy. Circulation 108(8):939–944

30.

http://www.fda.gov/medwatch/SAFETY/2005/Jan_PI/Serzone_PI.pdf. Accessed June 2, 2007

31.

Lesperance F, Frasure-Smith N, Laliberte MA et al (2003) An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry 48:695–701PubMed

32.

Roose SP, Dalack GW, Glassman AH, Woodring S, Walsh BT, Giardina EGV (1991) Cardiovascular effects of bupropion in depressed patients with heart disease. Am J Psychiatry 148:512–516PubMed

33.

Qin F, Shite J, Mao W, Liang C-S (2003) Selegiline attenuates cardiac oxidative stress and apoptosis in heart failure: association with improvement of cardiac function. Eur J Pharmacol 461(2–3):149–158PubMedCrossRef

34.

Nissen SE (2006) ADHD drugs and cardiovascular risk. New Engl J Med 354:1445–1448PubMedCrossRef

35.

Wilens TE, Hammerness PG, Biederman J et al (2005) Blood pressure changes associated with medication treatment of adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry 66(2):253–259PubMedCrossRef

36.

Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF III (2006) Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. Am J Geriat Psychiatry 14(2):181–185

37.

Writing Committee for the ENRICHD Investigators (2003) Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the enhancing recovery in coronary heart disease patients (ENRICHD) randomized trial. JAMA 289(23):3106–3116

38.

Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES (1984) Interpersonal psychotherapy of depression. Basic Books, New York

39.

Solimene MC (2007) Electroconvulsive therapy and the heart. Int J Cardiol 114(1):103PubMedCrossRef

40.

Zielinski RJ, Roose SP, Devanand DP, Woodring S, Sackeim H (1993) Cardiovascular complications of ECT in depressed patients with cardiac disease. Am J Psychiatry 150:904–909PubMed

41.

Magid M, Lapid MI, Sampson SM, Mueller PS (2005) Use of electroconvulsive therapy in a patient 10 days after myocardial infarction. J ECT 21(3):182–185PubMedCrossRef

42.

Nuttall GA, Bowersox MR, Douglass SB et al (2004) Morbidity and mortality in the use of electroconvulsive therapy. J ECT 20(4):237–241PubMedCrossRef

43.

Dolenc TJ, Barnes RD, Hayes DL, Rasmussen KG (2004) Electroconvulsive therapy in patients with cardiac pacemakers and implantable cardioverter defibrillators. Pacing Clin Electrophysiol 27(9):1257–1263PubMedCrossRef

44.

Rayburn BK. (1997) Electroconvulsive therapy in patients with heart failure or valvular heart disease. Convuls Ther 13(3):145–156PubMed

Title: Treatment of depression in patients with congestive heart failure
Author: Peter A. Shapiro
Publication date: 01-03-2009
Publisher: Springer US
Published in: Heart Failure Reviews / Issue 1/2009
Print ISSN: 1382-4147
Electronic ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-007-9058-6

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

At a glance: The STEP trials

Springer Medicine

Treatment of depression in patients with congestive heart failure

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2009

LVAD destination therapy: applying what we know about psychiatric evaluation and management from cardiac failure and transplant

Alcohol use and congestive heart failure: incidence, importance, and approaches to improved history taking

Psychobiology of depression/distress in congestive heart failure

Screening, diagnosis & monitoring of depression/distress in CHF patients

The use of cognitive behavioral therapy in the treatment of depression for individuals with CHF

Symptom perception in CHF: (why mind matters)

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page